Increased plasma and salivary nitrite and decreased bronchial contribution to exhaled NO in pulmonary arterial hypertension

European Journal of Clinical Investigation

Volumn 41, Issue 8, 2011, Pages 889-897

  Malinovschi, Andrei ^a   Henrohn, Dan ^a   Eriksson, André ^a   Lundberg, Jon O ^b   Alving, Kjell ^a   Wikström, Gerhard ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Exhaled nitric oxide; Nitrate; Nitrite; NO flow independent exchange parameters; Pulmonary hypertension

Indexed keywords

NITRATE; NITRIC OXIDE; NITRITE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; EXPIRED AIR; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SALIVA LEVEL;

ADULT; AGED; BREATH TESTS; BRONCHI; CASE-CONTROL STUDIES; EXHALATION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NITRATES; NITRIC OXIDE; NITRITES; RESPIRATORY FUNCTION TESTS; SALIVA;

EID: 79960090155     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02488.x     Document Type: Article

References (52)

1. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368-70.
2. Taylor DR, Pijnenburg MW, Smith AD, de Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006;61:817-27.
3. Persson MG, Zetterstrom O, Agrenius V, Ihre E, Gustafsson LE. Single-breath nitric oxide measurements in asthmatic patients and smokers. Lancet 1994;343:146-7.
4. Lundberg JO, Weitzberg E, Nordvall SL, Kuylenstierna R, Lundberg JM, Alving K. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome. Eur Respir J 1994;7:1501-4.
5. Tiev KP, Cabane J, Aubourg F, Kettaneh A, Ziani M, Mouthon L et al. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J 2007;30:26-30.
6. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010;138:682-92.
7. George SC, Hogman M, Permutt S, Silkoff PE. Modeling pulmonary nitric oxide exchange. J Appl Physiol 2004;96:831-9.
8. Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM et al. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med 2004;170:737-41.
9. Lehtimaki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur Respir J 2002;20:841-5.
10. Hogman M, Holmkvist T, Wegener T, Emtner M, Andersson M, Hedenstrom H et al. Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis. Respir Med 2002;96:24-30.
11. Paraskakis E, Zihlif N, Bush A. Nitric oxide production in PCD: possible evidence for differential nitric oxide synthase function. Pediatr Pulmonol 2007;42:876-80.
12. Malinovschi A, Janson C, Holm L, Nordvall L, Alving K. Basal and induced NO formation in the pharyngo-oral tract influences estimates of alveolar NO levels. J Appl Physiol 2009;106:513-9.
13. Zetterquist W, Marteus H, Kalm-Stephens P, Nas E, Nordvall L, Johannesson M et al. Oral bacteria - the missing link to ambiguous findings of exhaled nitrogen oxides in cystic fibrosis. Respir Med 2009;103:187-93.
14. Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med 2005;172:352-7.
15. Kaneko FT, Arroliga AC, Dweik RA, Comhair SA, Laskowski D, Oppedisano R et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998;158:917-23.
16. Rolla G, Colagrande P, Scappaticci E, Chiavassa G, Dutto L, Cannizzo S et al. Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. J Rheumatol 2000;27:1693-8.
17. Riley MS, Porszasz J, Miranda J, Engelen MP, Brundage B, Wasserman K. Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis. Chest 1997;111:44-50.
18. Archer SL, Djaballah K, Humbert M, Weir KE, Fartoukh M, Dall'ava-Santucci J et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998;158:1061-7.
19. Golbasi Z, Dincer S, Bayol H, Ugurlu B, Cicek D, Keles T et al. Increased nitric oxide in exhaled air in patients with rheumatic heart disease. Eur J Heart Fail 2001;3:27-32.
20. Machado RF, Londhe Nerkar MV, Dweik RA, Hammel J, Janocha A, Pyle J et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. Free Radic Biol Med 2004;37:1010-7.
21. Forrest IA, Small T, Corris PA. Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls. Clin Sci (Lond) 1999;97:99-102.
22. Ozkan M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung 2001;179:233-43.
23. Pinder AG, Pittaway E, Morris K, James PE. Nitrite directly vasodilates hypoxic vasculature via nitric oxide-dependent and -independent pathways. Br J Pharmacol 2009;157:1523-30.
24. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008;7:156-67.
25. Ingram TE, Pinder AG, Bailey DM, Fraser AG, James PE. Low-dose sodium nitrite vasodilates hypoxic human pulmonary vasculature by a means that is not dependent on a simultaneous elevation in plasma nitrite. Am J Physiol Heart Circ Physiol 2010;298:H331-9.
26. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
27. Tsoukias NM, Tannous Z, Wilson AF, George SC. Single-exhalation profiles of NO and CO2 in humans: effect of dynamically changing flow rate. J Appl Physiol 1998;85:642-52.
28. Condorelli P, Shin HW, Aledia AS, Silkoff PE, George SC. A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J Appl Physiol 2007;102:417-25.
29. Lundberg JO, Govoni M. Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic Biol Med 2004;37:395-400.
30. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
31. Malinovschi A, Janson C, Holmkvist T, Norback D, Merilainen P, Hogman M. Effect of smoking on exhaled nitric oxide and flow-independent nitric oxide exchange parameters. Eur Respir J 2006;28:339-45.
32. Rothe T, Karrer W, Schindler C. A single dose of Sildenafil does not enhance FeNO: a randomised, cross-over and placebo-controlled study. Respir Med 2010;104:788-93.
33. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
34. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, Westerhof N et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008;31:759-64.
35. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-28.
36. National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 2008;63(Suppl. 2):ii1-41.
37. Demoncheaux EA, Higenbottam TW, Kiely DG, Wong JM, Wharton S, Varcoe R et al. Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res 2005;42:133-6.
38. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005;25:1414-8.
39. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-l-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001;37:489-92.
40. Dimitroulas T, Giannakoulas G, Sfetsios T, Karvounis H, Dimitroula H, Koliakos G et al. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 2008;47:1682-5.
41. Burke CM, Glanville AR, Morris AJ, Rubin D, Harvey JA, Theodore J et al. Pulmonary function in advanced pulmonary hypertension. Thorax 1987;42:131-5.
42. Rastogi D, Ngai P, Barst RJ, Koumbourlis AC. Lower airway obstruction, bronchial hyperresponsiveness, and primary pulmonary hypertension in children. Pediatr Pulmonol 2004;37:50-5.
43. Zetterquist W, Pedroletti C, Lundberg JO, Alving K. Salivary contribution to exhaled nitric oxide. Eur Respir J 1999;13:327-33.
44. Kirsch M, Kemp-Harper B, Weissmann N, Grimminger F, Schmidt HH. Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling. FASEB J 2008;22:30-40.
45. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23.
46. Girgis RE, Gugnani MK, Abrams J, Mayes MD. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. Am J Respir Crit Care Med 2002;165:1587-91.
47. Tiev KP, Le Dong NN, Duong-Quy S, Hua-Huy T, Cabane J, Dinh-Xuan AT. Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis. Nitric Oxide 2009;20:200-6.
48. Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J et al. Peripheral airway obstruction in primary pulmonary hypertension. Thorax 2002;57:473-6.
49. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995;41:892-6.
50. Sungur M, Ocal B, Oguz D, Karademir S, Karakurt C, Senocak F. Plasma endothelin-1 and nitrate levels in Down's syndrome with complete atrioventricular septal defect-associated pulmonary hypertension: a comparison with non-Down's syndrome children. Eur J Pediatr 2009;168:593-7.
51. Govoni M, Jansson EA, Weitzberg E, Lundberg JO. The increase in plasma nitrite after a dietary nitrate load is markedly attenuated by an antibacterial mouthwash. Nitric Oxide 2008;19:333-7.
52. Palmerini CA, Zucchi A, Fioretti F, Arienti G. Erectile dysfunction and NO: variations of NO penile blood levels before and after sildenafil treatment. Int J Impot Res 2009;21:321-5.